Anticancer Compounds from Cyanobacteria and their Implications in Apoptosis

Area of Science:

• Natural Product Chemistry
• Pharmacology
• Biotechnology

Background:

• Cyanobacteria are a prolific source of bioactive metabolites with pharmacological potential.
• These compounds exhibit cytotoxicity against cancer cells through mechanisms including apoptosis induction and cell signaling modulation.
• The B-cell lymphoma 2 (Bcl-2) protein, a key regulator of apoptosis, is a significant target in cancer therapy.

Approach:

• This review explores cyanobacterial compounds as potential inhibitors of Bcl-2.
• Computational techniques including virtual screening, toxicity prediction, and drug-likeness analysis were employed to identify hit compounds.
• ADMET property prediction was performed on 23 identified compounds.

Key Points:

• Cyanobacterial compounds can induce cancer cell death via apoptosis and by modulating cell signaling pathways.
• Bcl-2 protein's role in inhibiting apoptosis makes it a significant target for developing new anti-tumor drugs.
• Dendroamide A and Welwitindolinone A were identified as the most stable and effective potential inhibitors of Bcl-2.

Conclusions:

• Cyanobacterial compounds represent a valuable resource for developing new anticancer drugs.
• Bcl-2 is a validated therapeutic target, and identified compounds offer leads for drug development.
• Further research into Dendroamide A and Welwitindolinone A could yield effective anti-tumor therapies.